New and Emerging Therapies in Psoriasis

被引：0
|
作者：
Leonardi, Craig L. [1 ,2 ]
Gordon, Kenneth B. [3 ]
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
[2] Cent Dermatol, St Louis, MO 63117 USA
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2014年 / 33卷
关键词：
Apremilast; brodalumab; interleukin-12/23; inhibitors; interleukin-17; ixekizumab; JAK; Janus kinase inhibitors; phosphodiesterase-4; psoriasis treatment; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; CHRONIC PLAQUE PSORIASIS; TO-SEVERE PSORIASIS; DOUBLE-BLIND; USTEKINUMAB; SAFETY; EFFICACY; TRIAL;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blacker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blacker) and tofacitinib (a Janus kinase inhibitor). (C) 2014 published by Frontline Medical Communications
引用
收藏
页码：S37 / S41
页数：5
相关论文
共 50 条
  • [31] New Topical Therapies for Psoriasis
    Le, Ana Maria
    Torres, Tiago
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (01) : 13 - 24
  • [32] Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events
    Palakornkitti, Pasita
    Nimmannitya, Kulsupa
    Rattanakaemakorn, Ploysyne
    ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2021, 39 (04) : 215 - 230
  • [33] A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
    Chudy-Onwugaje, Kenechukwu O.
    Christian, Kaci E.
    Farraye, Francis A.
    Cross, Raymond K.
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (05) : 820 - 830
  • [34] Side effects of biologic therapies in psoriasis
    Altenburg, A.
    Augustin, M.
    Zouboulis, C. C.
    HAUTARZT, 2018, 69 (04): : 290 - 297
  • [35] New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents
    Toussirot, Eric
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 275 - 282
  • [36] Kasr AL-Ainy's psoriasis unit protocol for the treatment of psoriasis, part II: biological therapies
    Rasheed, Hoda
    AEl-Moaty, Hesham A. Z.
    El-Komy, Mohamed H. M.
    Mashaly, Heba
    Sayed, Khadiga S.
    Hafez, Vanessa
    El-Mesidy, Marwa S.
    Said, Eman R.
    Amer, Marwa A.
    AlOrbani, Aya M.
    Saadi, Dina G.
    El-Kalioby, Mona
    Eid, Reem O.
    Azzazi, Yousra
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2019, 16 (02): : 73 - 80
  • [37] Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis
    Erichsen, C. Y.
    Jensen, P.
    Kofoed, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : 30 - 38
  • [38] Novel Psoriasis Therapies and Patient Outcomes, Part 2: Biologic Treatments
    Feely, Meghan A.
    Smith, Barry L.
    Weinberg, Jeffrey M.
    CUTIS, 2015, 95 (05): : 282 - 290
  • [39] Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study
    Esposito, M.
    Gisondi, P.
    Conti, A.
    Giunta, A.
    del Giglio, M.
    Di Mercurio, M.
    Veneziano, L.
    Ferrucci, G.
    Bianchi, L.
    Chimenti, S.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (05) : 863 - 869
  • [40] What's New in Psoriasis
    von Csiky-Sessoms, Stephanie
    Lebwohl, Mark
    DERMATOLOGIC CLINICS, 2019, 37 (02) : 129 - +
12345